
Michael D. Burkhart
Examiner (ID: 3350, Phone: (571)272-2915 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1636, 1638, 1633 |
| Total Applications | 1174 |
| Issued Applications | 608 |
| Pending Applications | 127 |
| Abandoned Applications | 453 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20193578
[patent_doc_number] => 20250270288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-28
[patent_title] => SYNTHETIC PATHWAY ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 19/201822
[patent_app_country] => US
[patent_app_date] => 2025-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19201822
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/201822 | Synthetic pathway activators | May 6, 2025 | Issued |
Array
(
[id] => 20212590
[patent_doc_number] => 12409224
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia
[patent_app_type] => utility
[patent_app_number] => 19/171465
[patent_app_country] => US
[patent_app_date] => 2025-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 63
[patent_no_of_words] => 32879
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19171465
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/171465 | Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia | Apr 6, 2025 | Issued |
Array
(
[id] => 20288552
[patent_doc_number] => 20250313795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-09
[patent_title] => Method and Apparatus for Producing CAR T Cells
[patent_app_type] => utility
[patent_app_number] => 19/070308
[patent_app_country] => US
[patent_app_date] => 2025-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21446
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19070308
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/070308 | Method and apparatus for producing CAR T cells | Mar 3, 2025 | Issued |
Array
(
[id] => 20033524
[patent_doc_number] => 20250171746
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-29
[patent_title] => PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 19/043304
[patent_app_country] => US
[patent_app_date] => 2025-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57659
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19043304
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/043304 | Pseudotyped viral particles, compositions comprising the same, and uses thereof | Jan 30, 2025 | Issued |
Array
(
[id] => 19692844
[patent_doc_number] => 20250011389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-09
[patent_title] => IMMUNE CELLS DEFECTIVE FOR SUV39H1
[patent_app_type] => utility
[patent_app_number] => 18/895296
[patent_app_country] => US
[patent_app_date] => 2024-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18685
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895296
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/895296 | Immune cells defective for SUV39H1 | Sep 23, 2024 | Issued |
Array
(
[id] => 19904319
[patent_doc_number] => 12281315
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-04-22
[patent_title] => Composition for regulating production of proteins
[patent_app_type] => utility
[patent_app_number] => 18/773146
[patent_app_country] => US
[patent_app_date] => 2024-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 137
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18773146
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/773146 | Composition for regulating production of proteins | Jul 14, 2024 | Issued |
Array
(
[id] => 19418752
[patent_doc_number] => 20240294875
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => Reprogrammed T Cell-Like NK Cells
[patent_app_type] => utility
[patent_app_number] => 18/658913
[patent_app_country] => US
[patent_app_date] => 2024-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12161
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18658913
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/658913 | Reprogrammed T Cell-Like NK Cells | May 7, 2024 | Pending |
Array
(
[id] => 19815021
[patent_doc_number] => 20250073228
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/654622
[patent_app_country] => US
[patent_app_date] => 2024-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14883
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654622
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/654622 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | May 2, 2024 | Pending |
Array
(
[id] => 19403961
[patent_doc_number] => 20240287472
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/647283
[patent_app_country] => US
[patent_app_date] => 2024-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647283
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/647283 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Apr 25, 2024 | Pending |
Array
(
[id] => 19745679
[patent_doc_number] => 20250034244
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-30
[patent_title] => BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 18/644724
[patent_app_country] => US
[patent_app_date] => 2024-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25856
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18644724
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/644724 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | Apr 23, 2024 | Pending |
Array
(
[id] => 19709291
[patent_doc_number] => 20250019433
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-16
[patent_title] => METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/597328
[patent_app_country] => US
[patent_app_date] => 2024-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 100431
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597328
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/597328 | METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY | Mar 5, 2024 | Pending |
Array
(
[id] => 19310483
[patent_doc_number] => 12036277
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Vaccination with mRNA-coded antigens
[patent_app_type] => utility
[patent_app_number] => 18/596451
[patent_app_country] => US
[patent_app_date] => 2024-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 32803
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18596451
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/596451 | Vaccination with mRNA-coded antigens | Mar 4, 2024 | Issued |
Array
(
[id] => 19512416
[patent_doc_number] => 20240344102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/431564
[patent_app_country] => US
[patent_app_date] => 2024-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431564
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/431564 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | Feb 1, 2024 | Pending |
Array
(
[id] => 19233996
[patent_doc_number] => 20240191188
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME
[patent_app_type] => utility
[patent_app_number] => 18/411732
[patent_app_country] => US
[patent_app_date] => 2024-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -137
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18411732
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/411732 | METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAME | Jan 11, 2024 | Pending |
Array
(
[id] => 19584979
[patent_doc_number] => 20240382536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER
[patent_app_type] => utility
[patent_app_number] => 18/537897
[patent_app_country] => US
[patent_app_date] => 2023-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18537897
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/537897 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER | Dec 12, 2023 | Pending |
Array
(
[id] => 19188113
[patent_doc_number] => 20240167026
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/526247
[patent_app_country] => US
[patent_app_date] => 2023-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 122776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18526247
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/526247 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE | Nov 30, 2023 | Pending |
Array
(
[id] => 19432590
[patent_doc_number] => 20240301088
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => CHIMERIC ANTIGEN RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/515458
[patent_app_country] => US
[patent_app_date] => 2023-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515458
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515458 | CHIMERIC ANTIGEN RECEPTOR | Nov 20, 2023 | Pending |
Array
(
[id] => 19234004
[patent_doc_number] => 20240191196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/511513
[patent_app_country] => US
[patent_app_date] => 2023-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511513
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/511513 | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE | Nov 15, 2023 | Pending |
Array
(
[id] => 19171014
[patent_doc_number] => 20240156988
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/506193
[patent_app_country] => US
[patent_app_date] => 2023-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506193
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/506193 | SYNTHETIC NUCLEIC ACIDS INCLUDING ASTROCYTE-DIRECTED PROMOTER CONSTRUCTS AND METHODS OF USING THE SAME | Nov 9, 2023 | Pending |
Array
(
[id] => 19113088
[patent_doc_number] => 20240124838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => METHOD FOR SEPARATING NEURAL CREST DERIVED CELL FROM PERIPHERAL BLOOD
[patent_app_type] => utility
[patent_app_number] => 18/379257
[patent_app_country] => US
[patent_app_date] => 2023-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18379257
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/379257 | METHOD FOR SEPARATING NEURAL CREST DERIVED CELL FROM PERIPHERAL BLOOD | Oct 11, 2023 | Abandoned |